{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:55:25Z","timestamp":1768308925357,"version":"3.49.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Inappropriate dosing of direct oral anticoagulants (DOACs) may increase the risk of thromboembolism or bleeding in patients with atrial fibrillation (AF). The inappropriate use of these medications presents a significant clinical challenge. Our study aimed to analyze the current utilization of rivaroxaban and edoxaban among Chinese patients with AF, as well as the factors influencing the use of nonstandard doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study evaluated patients diagnosed with AF between January 2017 and December 2023. Descriptive analyses were performed to summarize the characteristics of the study population. Inappropriate dosing was identified based on the guidelines. Multivariate analysis was performed to identify factors associated with inappropriate dosing in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,066 patients diagnosed with AF, comprising 852 individuals treated with rivaroxaban and 214 individuals treated with edoxaban, were included. Their median age was 69 years, and 58.7% of them were males. Among them, 573 patients (53.8%) received inappropriate dosages. Among the patients prescribed rivaroxaban, 503 (59.0%) were underdosed and eight (0.9%) were overdosed. Among the patients prescribed edoxaban, 49 patients (22.9%) were underdosed and 13 patients (6.1%) were overdosed. Multivariate analysis identified independent factors associated with inappropriate medication dosing, including advanced age [adjusted odds ratio (OR) 1.031, 95% confidence interval (CI) 1.010\u20131.052], combined use of antiplatelet drugs (adjusted OR 1.649, 95% CI 1.111\u20132.447), and reduced use of dronedarone (adjusted OR 0.332, 95% CI 0.126\u20130.877).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The incidence of inappropriate DOAC dosing in Chinese patients with AF was high. Advanced age, the concurrent use of antiplatelet medications, and the nonuse of dronedarone have been identified as independent factors associated with inappropriate dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1694976","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:32:30Z","timestamp":1768285950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors influencing the inappropriate dosing of rivaroxaban and edoxaban in Chinese hospitalized patients with atrial fibrillation"],"prefix":"10.3389","volume":"12","author":[{"given":"Ying","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/clc.22272","article-title":"Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry","volume":"37","author":"Kirchhof","year":"2014","journal-title":"Clin Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cjca.2019.05.024","article-title":"Risk of hospital admissions in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"35","author":"Meyre","year":"2019","journal-title":"Can J Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ahj.2014.02.003","article-title":"Drivers of hospitalization for patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF)","volume":"167","author":"Steinberg","year":"2014","journal-title":"Am Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1477-9560-11-11","article-title":"Laboratory assessment of rivaroxaban: a review","volume":"11","author":"Samama","year":"2013","journal-title":"Thromb J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12959-023-00527-x","article-title":"Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF phase III registry: trends in antithrombotic therapy use in China","volume":"21","author":"Liu","year":"2023","journal-title":"Thromb J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40256-016-0161-8","article-title":"Suboptimal use of oral anticoagulants in atrial fibrillation: has the Introduction of direct oral anticoagulants improved prescribing practices?","volume":"16","author":"Alamneh","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2147\/CLEP.S358277","article-title":"Effectiveness and safety of reduced and standard daily doses of direct oral anticoagulants in patients with nonvalvular atrial fibrillation: a cohort study using national database representing the Japanese population","volume":"14","author":"Kubota","year":"2022","journal-title":"Clin Epidemiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants","volume":"76","author":"Camm","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bcp.15017","article-title":"Determinants for under- and overdosing of direct oral anticoagulants and physicians\u2019 implementation of clinical pharmacists\u2019 recommendations","volume":"88","author":"Moudallel","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11239-021-02528-x","article-title":"Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation","volume":"53","author":"Li","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10557-022-07409-w","article-title":"Prevalence and associated factors of inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation: the ANATOLIA-AF study","volume":"38","author":"Kocaba\u015f","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"euad302","DOI":"10.1093\/europace\/euad302","article-title":"Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French national prospective registry: PAFF","volume":"25","author":"Guenoun","year":"2023","journal-title":"Europace"},{"key":"B20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2022.09.073","article-title":"Off-label dose direct oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation: a new evidence of Asian dose","volume":"371","author":"Xu","year":"2023","journal-title":"Int J Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.hrthm.2020.07.022","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation","volume":"17","author":"Chan","year":"2020","journal-title":"Heart Rhythm"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","article-title":"Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"Chao","year":"2019","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/bcp.14127","article-title":"Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review","volume":"86","author":"Santos","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10557-021-07171-5","article-title":"Efficacy and safety of clinically driven low-dose treatment with direct oral anticoagulants in Asians with atrial fibrillation: a systematic review and meta-analysis","volume":"36","author":"Choi","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1161\/STROKEAHA.119.025623","article-title":"Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation","volume":"50","author":"Cheng","year":"2019","journal-title":"Stroke"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e007633","DOI":"10.1161\/JAHA.117.007633","article-title":"Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II)","volume":"7","author":"Steinberg","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e26883","DOI":"10.1097\/MD.0000000000026883","article-title":"Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: a PRISMA-compliant article","volume":"100","author":"Kim","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.3390\/jcm11247423","article-title":"Oral anticoagulant use and appropriateness in elderly patients with atrial fibrillation in complex clinical conditions: aCONVENIENCE study","volume":"11","author":"Bonanad","year":"2022","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.hrthm.2018.08.016","article-title":"Net clinical benefit of anticoagulant treatments in elderly patients with nonvalvular atrial fibrillation: experience from the real world","volume":"16","author":"Alnsasra","year":"2019","journal-title":"Heart Rhythm"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e2015943","DOI":"10.1001\/jamanetworkopen.2020.15943","article-title":"Evaluation of the age, biomarkers, and clinical history-bleeding risk score in patients with atrial fibrillation with combined aspirin and anticoagulation therapy enrolled in the ARISTOTLE and RE-LY trials","volume":"3","author":"Hijazi","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","article-title":"Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study","volume":"110","author":"Gronich","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/eurjhf\/hft004","article-title":"Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade atrial fibrillation study","volume":"15","author":"Potpara","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/FJC.0000000000000913","article-title":"Appropriateness of the direct oral anticoagulants dosing in the Middle East gulf region","volume":"77","author":"Anouassi","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e2317156","DOI":"10.1001\/jamanetworkopen","article-title":"Analysis of oral anticoagulant dosing and adherence to therapy among patients with nonvalvular atrial fibrillation","volume":"6","author":"Rymer","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/ehjcvp\/pvz069","article-title":"Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study","volume":"6","author":"Olsen","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1694976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:32:31Z","timestamp":1768285951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1694976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":37,"alternative-id":["10.3389\/fcvm.2025.1694976"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1694976","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1694976"}}